{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:08:00Z","timestamp":1769047680469,"version":"3.49.0"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01511","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T23:50:14Z","timestamp":1578441014000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Nephrotoxicity in a Patient With Inadequate Pain Control: Potential Role of Pharmacogenetic Testing for Cytochrome P450 2D6 and Apolipoprotein L1"],"prefix":"10.3389","volume":"10","author":[{"given":"Emma M.","family":"Tillman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Skaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Eadon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/jat\/bks019","article-title":"Relationship between the concentration of hydrocodone and its conversion to hydromorphone in chronic pain patients using urinary excretion data","volume":"36","author":"Barakat","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/clpt.2013.254","article-title":"Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update","volume":"95","author":"Crews","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1053\/j.ajkd.2018.06.020","article-title":"APOL1-Associated nephropathy: a key contributor to racial disparities in CKD","volume":"72","author":"Freedman","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.semnephrol.2013.07.004","article-title":"APOL1 and nephropathy progression in populations of African ancestry","volume":"33","author":"Freedman","year":"2013","journal-title":"Semin. Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S0140-6736(06)69255-6","article-title":"Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother","volume":"368","author":"Koren","year":"2006","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0376-8716(98)00169-0","article-title":"Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys","volume":"54","author":"Lelas","year":"1999","journal-title":"Drug Alcohol Depend."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/AJP.0000000000000214","article-title":"Individualized hydrocodone therapy based on phenotype, pharmacogenetics, and pharmacokinetic dosing","volume":"31","author":"Linares","year":"2015","journal-title":"Clin. J. Pain."},{"key":"B8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1046\/j.0306-5251.2001.01398.x","article-title":"Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?","volume":"51","author":"Martin","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/fampra\/cms086","article-title":"Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review","volume":"30","author":"Nderitu","year":"2013","journal-title":"Fam. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u2013an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T23:50:15Z","timestamp":1578441015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":11,"alternative-id":["10.3389\/fphar.2019.01511"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01511","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"article-number":"1511"}}